Corvus Pharmaceuticals Prices Upsized Public Stock Offering
Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it has commenced the pricing of an upsized underwritten public offering of 7,900.677 shares of its common stock at a price to the public of $ 22.5 million. Thus, deducting the estimated underwriting discounts and commissions, including the estimated offering expenses, the Corvus is payable, which … Read more



